연구동향 분석

Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma

안효정 고경혁 이정희 이종실 김동철 양정욱 김민혜 김진평 정은정 송대현 2018년

논문상세정보
인용/피인용

' Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma' 의 참고문헌

  • Viral immune evasion due to persistence of activated T cells without effector function
    Zajac AJ [1998]
  • Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer
    Bastman JJ [2016]
  • Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer
    Park IH [2017]
  • Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    Dong H [2002]
  • The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now
  • The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
    Ness N [2017]
  • The blockade of immune checkpoints in cancer immunotherapy
    Pardoll DM [2012]
  • The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy
    Jin S [2017]
  • Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer
    French JD [2012]
  • Programmed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients
    Botti G [2017]
  • Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma
    Jiang Y [2017]
  • Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors
    Chovanec M [2017]
  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    Herbst RS [2016]
  • PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
    Fontugne J [2017]
  • PD-L1 expression in papillary renal cell carcinoma
    Motoshima T [2017]
  • PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
    한지헌 [2017]
  • PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes
    Zhou Y [2017]
  • Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors
  • Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression
    Song DH [2016]
  • Molecular signature of CD8+ T cell exhaustion during chronic viral infection
    Wherry EJ [2007]
  • Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
    Gravelle P [2017]
  • KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
    Chen N [2017]
  • Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy
    Thompson RH [2007]
  • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    Freeman GJ [2000]
  • Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
    Chen L [2004]
  • An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer
    Nixon IJ [2016]